{"ok":true,"nota":{"id":"dcf727ea72f1edb9","slug":"un-receptor-de-celulas-inmunes-logra-mas-expresion-con-una-parte-veint-dcf727","titulo":"Un receptor de células inmunes logra más expresión con una parte veinte veces más corta","resumen":"Investigadores rediseñaron el dominio intracelular de un receptor de células T con ayuda de agentes de IA en tres rondas de mejoras. El diseño resultante es menos de un tercio del largo del estándar clínico y aumentó la expresión y la muerte de células tumorales en pruebas de laboratorio.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Bai, L., Kumar, A., Desai, H. J., Li, J., de Alwis, D. P., Hazuda, D., Grigoryan, G., Wang, W., Yi, J.","url":"https://www.biorxiv.org/content/10.64898/2026.10.28.762481v1?rss=1","imagen":"/hoy/portada/dcf727ea72f1edb9","tema":"ciencia","subtemas":["inmunoterapia","células car-t","cáncer","inteligencia artificial","ingeniería genética"],"entidades":["bioRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-29T00:00:00.000Z","indexTs":"2026-10-30T00:12:24.320Z","hash":"4bfd0bc517b792b65135a772c58e9bc9326838e10e7691d3736a8fe7a38ea761","tsa":{"time":"Oct 30 00:13:11 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Las terapias con células CAR-T ya tratan algunos cánceres de sangre, pero el diseño del receptor determina cuánto tiempo sobreviven las células y cuánto atacan. Un componente más corto y eficiente podría reducir el costo y facilitar la combinación de varios receptores en una misma célula. Todavía son resultados en células y en laboratorio, no en personas.","quienFirma":"bioRxiv (preprint, equipo de ingeniería de células inmunes)","confianza":"preprint","consulta":null},"sello":{"hash":"4bfd0bc517b792b65135a772c58e9bc9326838e10e7691d3736a8fe7a38ea761","sello":"193109c9845ba6cf2bd0c9ebff46a921f757bf0b535596a26a582f0a8c100f30","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6596271,"aleatorio":"475c20d708c2524a0cdebe4af77dfec4e122e8884ff50a0b62e90561b365834d","tiempo":"2026-10-30T00:12:30.000Z"},"nist":{"cadena":2,"pulso":2005069,"salida":"B55044227417F6923433CBC2983B4E344B47070946A68BA8DC65AF11249229CBE5D9905DB414536D56361BCB8273863C09AB5DD19B3BEC1B620F044B5C5E59D8","tiempo":"2026-10-30T00:11:00.000Z"},"noAntes":"2026-10-30T00:12:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 30 00:13:11 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Refactored intracellular domains enhance CAR expression and function","descripcion":"Chimeric antigen receptor (CAR) intracellular domains (ICDs) couple antigen recognition to T-cell activation. Here we worked with AI agents to refactor CAR ICDs, proposing designs and refining them as measurements accumulated over three rounds. This approach yielded KRGR-{zeta}1-40, a 45-amino-acid ICD less than a third the length of the clinical 4-1BB-CD3{zeta} (BB{zeta}) ICD. Compared with BB{zeta}, KRGR-{zeta}1-40 increased CAR surface expression and antigen-driven IFN-{gamma} release, without detectable antigen-independent IFN-{gamma} release. KRGR-{zeta}1-40 extended CAR expression and target-cell killing after transient mRNA delivery, supported the expression of four CARs from a shared","pubDate":"2026-10-29","url":"https://www.biorxiv.org/content/10.64898/2026.10.28.762481v1?rss=1"},"indexado":"2026-10-30T00:12:24.320Z"}}